AU2005300315A1 - CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer - Google Patents
CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer Download PDFInfo
- Publication number
- AU2005300315A1 AU2005300315A1 AU2005300315A AU2005300315A AU2005300315A1 AU 2005300315 A1 AU2005300315 A1 AU 2005300315A1 AU 2005300315 A AU2005300315 A AU 2005300315A AU 2005300315 A AU2005300315 A AU 2005300315A AU 2005300315 A1 AU2005300315 A1 AU 2005300315A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- ctla4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62485604P | 2004-11-04 | 2004-11-04 | |
US60/624,856 | 2004-11-04 | ||
PCT/IB2005/003307 WO2006048749A1 (fr) | 2004-11-04 | 2005-10-24 | Anticorps ctla-4 et inhibiteur de l'aromatase ou traitement combine du cancer du sein |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2005300315A1 true AU2005300315A1 (en) | 2006-05-11 |
Family
ID=35825412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005300315A Abandoned AU2005300315A1 (en) | 2004-11-04 | 2005-10-24 | CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1819735A1 (fr) |
JP (1) | JP2008518902A (fr) |
KR (1) | KR20070067702A (fr) |
CN (1) | CN101052655A (fr) |
AR (1) | AR053651A1 (fr) |
AU (1) | AU2005300315A1 (fr) |
BR (1) | BRPI0515735A2 (fr) |
CA (1) | CA2586844A1 (fr) |
IL (1) | IL182244A0 (fr) |
MX (1) | MX2007003804A (fr) |
NO (1) | NO20072576L (fr) |
RU (1) | RU2007114111A (fr) |
TW (1) | TW200621804A (fr) |
WO (1) | WO2006048749A1 (fr) |
ZA (1) | ZA200702577B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2605796A1 (fr) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Compositions pharmaceutiques et methodes comprenant une combinaison d'un modulateur selectif du recepteur de l'oestrogene et d'un inhibiteur de l'aromatase |
SG163583A1 (en) * | 2005-07-07 | 2010-08-30 | Coley Pharm Group Inc | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
CA2647282A1 (fr) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Polytherapie a base d'un anticorps anti-ctla4 |
CN101909693A (zh) * | 2008-01-08 | 2010-12-08 | 百时美施贵宝公司 | 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合 |
WO2010014784A2 (fr) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
EA027693B1 (ru) | 2008-09-26 | 2017-08-31 | Токаджен Инк. | Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации |
WO2010040105A2 (fr) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Protéines de liaison multicibles antagonistes de cd86 |
DK2769737T3 (en) * | 2009-07-20 | 2017-07-24 | Bristol Myers Squibb Co | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES |
EP2710137B1 (fr) | 2011-03-10 | 2018-09-19 | Provectus Pharmatech, Inc. | Une combinaison de rose bengale et un antikorps anti-ctla4 pour le traitement du cancer |
KR102004559B1 (ko) | 2011-08-30 | 2019-07-26 | 아스텍스 파마수티컬스, 인크. | 데시타빈 유도체 제제 |
HUE044352T2 (hu) * | 2011-10-14 | 2019-10-28 | Hoffmann La Roche | Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére |
PE20142406A1 (es) | 2012-05-04 | 2015-01-23 | Pfizer | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna |
CN103768596B (zh) * | 2012-10-17 | 2016-06-22 | 苏州丁孚靶点生物技术有限公司 | 用于肿瘤治疗的组合产品、其用途及相关方法 |
CN104884627A (zh) | 2012-10-25 | 2015-09-02 | 托卡根公司 | 具有小型启动子盒的逆转录病毒载体 |
CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
EP3057990B1 (fr) * | 2013-10-18 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Compositions comprenant une combinaison d'antagoniste du vegf et d'anticorps anti-ctla-4 |
JP6768722B2 (ja) | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
EA201890640A1 (ru) | 2015-09-04 | 2018-09-28 | Токаджен Инк. | Рекомбинантные векторы, содержащие пептид 2а |
CN106883298B (zh) * | 2015-12-16 | 2021-12-17 | 上海康岱生物医药技术股份有限公司 | 双特异性偶联抗体及其制法和用途 |
SG11201805835WA (en) | 2016-01-08 | 2018-08-30 | Replimune Ltd | Modified oncolytic virus |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
JP7198666B2 (ja) * | 2016-08-26 | 2023-01-04 | 哲治 奥野 | 微小血管血流低減剤およびその利用 |
WO2018098352A2 (fr) | 2016-11-22 | 2018-05-31 | Jun Oishi | Ciblage d'expression du point de contrôle immunitaire induit par kras |
HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
WO2018167780A1 (fr) * | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Méthodes de diagnostic et de traitement du cancer |
BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
WO2021173870A1 (fr) * | 2020-02-27 | 2021-09-02 | University Of Washington | Composition et procédé pour préparer une suspension injectable à action prolongée contenant de multiples médicaments anticancéreux |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
-
2005
- 2005-10-24 CA CA002586844A patent/CA2586844A1/fr not_active Abandoned
- 2005-10-24 CN CNA2005800377929A patent/CN101052655A/zh active Pending
- 2005-10-24 KR KR1020077010096A patent/KR20070067702A/ko not_active Application Discontinuation
- 2005-10-24 AU AU2005300315A patent/AU2005300315A1/en not_active Abandoned
- 2005-10-24 WO PCT/IB2005/003307 patent/WO2006048749A1/fr active Application Filing
- 2005-10-24 MX MX2007003804A patent/MX2007003804A/es unknown
- 2005-10-24 BR BRPI0515735-8A patent/BRPI0515735A2/pt not_active IP Right Cessation
- 2005-10-24 EP EP05798369A patent/EP1819735A1/fr not_active Ceased
- 2005-10-24 RU RU2007114111/13A patent/RU2007114111A/ru unknown
- 2005-10-24 JP JP2007538539A patent/JP2008518902A/ja not_active Withdrawn
- 2005-11-01 TW TW094138271A patent/TW200621804A/zh unknown
- 2005-11-02 AR ARP050104588A patent/AR053651A1/es not_active Application Discontinuation
-
2007
- 2007-03-27 IL IL182244A patent/IL182244A0/en unknown
- 2007-03-28 ZA ZA200702577A patent/ZA200702577B/en unknown
- 2007-05-21 NO NO20072576A patent/NO20072576L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200621804A (en) | 2006-07-01 |
CN101052655A (zh) | 2007-10-10 |
MX2007003804A (es) | 2007-04-23 |
AR053651A1 (es) | 2007-05-16 |
ZA200702577B (en) | 2008-07-30 |
IL182244A0 (en) | 2007-09-20 |
CA2586844A1 (fr) | 2006-05-11 |
RU2007114111A (ru) | 2008-12-10 |
NO20072576L (no) | 2007-08-03 |
WO2006048749A1 (fr) | 2006-05-11 |
KR20070067702A (ko) | 2007-06-28 |
BRPI0515735A2 (pt) | 2011-10-11 |
JP2008518902A (ja) | 2008-06-05 |
EP1819735A1 (fr) | 2007-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005300315A1 (en) | CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer | |
AU2005264063B2 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
EP2699598B1 (fr) | Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer | |
US20090074787A1 (en) | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer | |
EP1868644A1 (fr) | Traitement du cancer de la prostate au moyen d'anticorps anti-ctla4 et d'une hormonotherapie | |
WO2021228178A1 (fr) | Compositions et méthodes pour le traitement du cancer | |
WO2021227156A1 (fr) | Compositions et méthodes pour le traitement du cancer | |
WO2022150557A1 (fr) | Polythérapie utilisant un anticorps anti-fucosyl-gm1 | |
AU2021212193A1 (en) | Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |